“This is a fantastic example of what St. Louis-based innovation, talent and resources can do to build biopharma companies that will make a difference,” said John McKearn, RiverVest managing director and Tioma board chairman.
Also in this issue:
RiverVest’s Fund II Continues to perform in Top 5% of VC funds
RiverVest Adds Analyst in St. Louis Office
Portfolio company news from Allakos, Amplyx, Otonomy and Securus